



## A CELEBRATION OF INNOVATION



**November 11, 2015**

*presented with support from*

**LSU Health Sciences Center  
Office of Academic Affairs**

**The Foundation for the  
LSU Health Sciences Center**

# PROGRAM

- 11:00 AM**      Networking
- 11:15 AM**      Welcome and Introduction  
*Larry H. Hollier, MD*  
*Chancellor*
- 11:20 AM**      Keynote Address  
*P.K. Scheerle, RN*  
*CEO & Founder, Gifted Healthcare*
- 11:30 AM**      Awards Presentation  
*Patrick E. Reed, MS, RTTP*  
*Director, Office of Technology Management*
- Noon**            Closing Remarks  
*Joseph M. Moerschbaeche, III, PhD*  
*Vice Chancellor for Academic Affairs*
- 12:15 PM**      Luncheon  
*Chancellor's Dining Room, 3<sup>rd</sup> Floor*

# Innovation Award Winners & Achievements

## Haydee E. P. Bazan, PhD

🏆 US Patent 8,729,128, "Lipoxin A4 Protection for Cornea Endothelial Cells" issued 5/20/14

*Dr. Haydee Bazan helped develop a novel therapeutic compound that reduces swelling, and enhances survival, proliferation and wound healing of damaged corneal cells. This compound can also be used to form an improved storage solution for corneal tissue prior to transplantation.*

## Nicolas G. Bazan, MD, PhD

🏆 US Patent 8,729,128, "Lipoxin A4 Protection for Cornea Endothelial Cells" issued 5/20/14 (description above)

🏆 Exclusive License Agreement for analgesic therapeutic compounds, effective 12/11/13

## Chu Chen, PhD

🏆 Exclusive License Agreement for a therapeutic compound cocktail for neurodegenerative diseases, effective 1/15/15

## William C. Claycomb, PhD

🏆 Nonexclusive License Agreement for novel research materials, effective 4/17/14

## Kevin N. Dietz, PhD

🏆 US Patent 8,304,521, "Phospho-specific Anti-Pax3 Antibodies" issued 11/6/12

*Dr. Dietz helped develop a panel of highly-specific antibodies to key regulatory modifications on the protein Pax3 and its cancer-causing counterpart Pax3-FOXO1. Such antibodies present a useful tool for a broad array of applications, including potential as both basic research and clinical uses.*

🏆 Nonexclusive License Agreement for novel research materials, effective 6/30/13

🏆 Nonexclusive License Agreement for novel research materials, effective 12/11/14

## Jeffrey D. Erickson, PhD

🏆 Nonexclusive License Agreement for novel research materials, effective 3/1/15

## Paul Fidel, Jr., PhD

🏆 US Patent 8,753,113, "Removable Intraoral Device for Rodent Research," issued 6/17/14

*Dr. Fidel helped invent a simple, removable intraoral device broadly applicable to research involving prosthodontics materials, biofilms, or prosthetic-associated infections.*

## Angela Foley, MS, MT (ASCP)

🏆 Exclusive License Agreement for copyright-protected case-based educational materials for hematology, effective 5/1/14

### **Timothy P. Foster, PhD**

📌 US Patent 9,011,845, "Methods for Treatment of Inflammatory and Infectious Viral Diseases," issued 4/21/15

*Dr. Foster helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.*

📌 US Patent 8,877,183, "Therapeutic Use of Arginase for the Amelioration of Pathogen- and Inflammation-mediated Ocular Disease," issued 11/4/14

*Dr. Foster helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.*

### **Harry J. Gould, III, MD, PhD**

📌 US Patent 8,921,320, "Targeted Osmotic Lysis of Cancer Cells," issued 12/30/14

*Dr. Gould helped develop a new therapeutic method to destroy cancer cells called Targeted Osmotic Lysis.*

📌 Limited Right of Exclusive Negotiation Agreement for a therapeutic method for cancer treatment, effective 4/8/13

### **Daniel S. Haun, MHS**

📌 Exclusive License Agreement for copyright-protected case-based educational materials for hematology, effective 5/1/14

### **Jiucheng He, MD, PhD**

📌 US Patent 8,729,128, "Lipoxin A4 Protection for Endothelial Cells," issued 5/20/14

*Dr. He helped develop a novel therapeutic compound that reduces swelling, and enhances survival, proliferation and wound healing of damaged corneal cells. This compound can also be used to form an improved storage solution for corneal tissue prior to transplantation.*

### **James M. Hill, PhD**

📌 US Patent 9,011,845, "Methods for Treatment of Inflammatory and Infectious Viral Diseases," issued 4/21/15

*Dr. Hill helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.*

📌 US Patent 8,877,183, "Therapeutic Use of Arginase for the Amelioration of Pathogen- and Inflammation-mediated Ocular Disease," issued 11/4/14

*Dr. Hill helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.*

### **Charles W. Hilton, MD**

📌 US Patent 8,393,905, "An Improved Medical Simulation Computer System," issued 3/12/13

*Dr. Hilton helped develop a medical simulation system that provides a more realistic training method for doctors. This new system allows for multiple executing simulated scenarios to exchange information and communicate status.*

📌 LIFT<sup>2</sup> Grant, "Development and Dissemination of a Software Interface," awarded 5/5/15

Dr. Hilton is optimizing a medical simulation system that provides a more realistic training method for doctors.

### **Andrew Hollenbach, PhD**

📌 US Patent 8,304,521, "Phospho-specific Anti-Pax3 Antibodies," issued 11/6/12

*Dr. Hollenbach helped develop a panel of highly-specific antibodies to key regulatory modifications on the protein Pax3 and its cancer-causing counterpart Pax3-FOXO1. Such antibodies present a useful tool for a broad array of applications, including potential as both basic research and clinical uses.*

📌 Nonexclusive License Agreement for novel research materials, effective 6/30/13

📌 Nonexclusive License Agreement for novel research materials, effective 12/11/14

### **Daniel R. Kapusta, PhD**

📌 LIFT<sup>2</sup> grant, "Kappa-opioid Agonists for Therapeutic Uses," awarded 7/15/14

*Dr. Kapusta is testing compounds to protect, prevent and treat kidney injury.*

### **Aaron D. Martin, MD, MPH**

📌 LIFT<sup>2</sup> Grant, "Apparatus and Method for Tissue Approximation and Fixation in Tubular Biologic Structures," awarded 7/15/14

*Dr. Martin is developing a prototype and testing of a biodegradable urethral scaffold to treat children with urinary conditions*

### **Charles Nichols, PhD**

📌 Exclusive License Agreement for an anti-inflammatory therapeutic compound, effective 6/8/15

### **Augusto Ochoa, MD**

📌 US Patent 9,011,845, "Methods for Treatment of Inflammatory and Infectious Viral Diseases," issued 4/21/15

*Dr. Ochoa helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.*

📌 US Patent 8,877,183, "Therapeutic Use of Arginase for the Amelioration of Pathogen- and Inflammation-mediated Ocular Disease," issued 11/4/14

*Dr. Ochoa helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.*

### **John T. Paige, MD**

🔗 LIFT<sup>2</sup> Grant, "Development and Dissemination of a Software Interface," awarded 5/5/15

*Dr. Paige is optimizing a medical simulation system that provides a more realistic training method for doctors.*

### **Dennis Paul, PhD**

🔗 US Patent 8,921,320, "Targeted Osmotic Lysis of Cancer Cells," issued 12/30/14

*Dr. Paul helped develop a new therapeutic method to destroy cancer cells called Targeted Osmotic Lysis.*

🔗 Limited Right of Exclusive Negotiation Agreement for a therapeutic method for cancer treatment, effective 4/8/13

🔗 Exclusive License Agreement for analgesic therapeutic compounds, effective 12/11/13

### **Francesca Peruzzi, PhD**

🔗 LIFT<sup>2</sup> Grant, "miR-3189-3p as a Tumor Suppressor," awarded 5/5/15

*Dr. Peruzzi is developing a small construct for the treatment of glioblastoma, the most common and most aggressive malignant brain tumor.*

### **Seth Pincus, MD**

🔗 LIFT<sup>2</sup> Grant, "Improved Double Variable Domain Antibodies to HIV," awarded 5/5/15

*Dr. Pincus is developing broadly neutralizing anti-HIV antibodies for the prevention and treatment of HIV infection.*

### **Alison J. Quayle, PhD**

🔗 Nonexclusive License Agreement for novel research materials, effective 12/11/14

🔗 Nonexclusive License Agreement for novel research materials, effective 1/1/15

### **Eugene A. Woltering, MD, FACS**

🔗 US Patent 8,334,000, "Antiangiogenic Agents from Plant Extracts, Gallic Acid, and Derivatives," issued 12/18/12

*Dr. Woltering helped develop a method to inhibit angiogenesis, or the growth of new blood vessels, using a natural extract from the Rubus plant. This method may be used to treat diseases whose pathogenesis includes an increase in angiogenesis, such as psoriasis.*

🔗 US Patent 8,349,374, "Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Extracts of Noni Juice," issued 1/8/13

*Dr. Woltering helped develop a method to inhibit angiogenesis, or the growth of new blood vessels, using an extract from the Noni plant. This method may be used to treat diseases whose pathogenesis includes an increase in angiogenesis, such as psoriasis.*

🔗 Limited Right of Exclusive Negotiation Agreement for a diagnostic imaging agent, effective 3/16/15

### **Hong Xin, MD, PhD**

💡 LIFT<sup>2</sup> Grant, "Peptide Vaccines and Related Antibodies Protect against Fungal Infections," awarded 5/5/15

*Dr. Xin is developing peptide vaccines and related antibodies for the active and passive immunization against candidiasis.*

### **Xiaoming Xu, PhD**

💡 US Patent 8,217,173, "New Fluoride-Releasing Compositions," issued 7/10/12

*Dr. Xu developed novel fluoride-releasing compositions that can be include in different dental materials, such as restorative fillings, to reduce the number of cavities in a patient, particular those occurring on the margins of the restorative materials.*

💡 US Patent 8,598,381, "New Fluoride-Releasing Compositions," issued 12/3/13

💡 LIFT<sup>2</sup> Grant, "Antimicrobial Thermoplastic Polyurethanes," awarded 7/15/14

*Dr. Xu is developing antimicrobial materials to reduce the chance of hospital infections from invasive medical devices.*

### **Alika Yu, DDS**

💡 US Patent 8,753,113, "Removable Intraoral Device for Rodent Research," issued 6/17/14

*Dr. Yu helped invent a simple, removable intraoral device broadly applicable to research involving prosthodontics materials, biofilms, or prosthetic-associated infections.*

### **Jian Zhang, PhD**

💡 Exclusive License Agreement for a therapeutic compound cocktail for neurodegenerative diseases, effective 1/15/15



**Office of Technology Management**  
<http://lsuh.sc/otm>